Analysts anticipate Genmab to report an earnings per share (EPS) of $0.35.
The market awaits Genmab's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Past Earnings Performance
During the last quarter, the company reported an EPS missed by $0.02, leading to a 2.36% drop in the share price on the subsequent day.
Here's a look at Genmab's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
0.33
0.14
4.02
EPS Actual
0.31
0.29
0.36
0.47
Price Change %
-2.0%
7.000000000000001%
2.0%
5.0%
Market Performance of Genmab's Stock
Shares of Genmab were trading at $22.78 as of November 04. Over the last 52-week period, shares are down 26.52%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Analyst Views on Genmab
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Genmab.
A total of 10 analyst ratings have been received for Genmab, with the consensus rating being Buy. The average one-year price target stands at $46.2, suggesting a potential 102.81% upside.
Comparing Ratings Among Industry Peers
In ...